HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Functional cognitive disorder: dementia's blind spot.

Abstract
An increasing proportion of cognitive difficulties are recognized to have a functional cause, the chief clinical indicator of which is internal inconsistency. When these symptoms are impairing or distressing, and not better explained by other disorders, this can be conceptualized as a cognitive variant of functional neurological disorder, termed functional cognitive disorder (FCD). FCD is likely very common in clinical practice but may be under-diagnosed. Clinicians in many settings make liberal use of the descriptive term mild cognitive impairment (MCI) for those with cognitive difficulties not impairing enough to qualify as dementia. However, MCI is an aetiology-neutral description, which therefore includes patients with a wide range of underlying causes. Consequently, a proportion of MCI cases are due to non-neurodegenerative processes, including FCD. Indeed, significant numbers of patients diagnosed with MCI do not 'convert' to dementia. The lack of diagnostic specificity for MCI 'non-progressors' is a weakness inherent in framing MCI primarily within a deterministic neurodegenerative pathway. It is recognized that depression, anxiety and behavioural changes can represent a prodrome to neurodegeneration; empirical data are required to explore whether the same might hold for subsets of individuals with FCD. Clinicians and researchers can improve study efficacy and patient outcomes by viewing MCI as a descriptive term with a wide differential diagnosis, including potentially reversible components such as FCD. We present a preliminary definition of functional neurological disorder-cognitive subtype, explain its position in relation to other cognitive diagnoses and emerging biomarkers, highlight clinical features that can lead to positive diagnosis (as opposed to a diagnosis of exclusion), and red flags that should prompt consideration of alternative diagnoses. In the research setting, positive identifiers of FCD will enhance our recognition of individuals who are not in a neurodegenerative prodrome, while greater use of this diagnosis in clinical practice will facilitate personalized interventions.
AuthorsHarriet A Ball, Laura McWhirter, Clive Ballard, Rohan Bhome, Daniel J Blackburn, Mark J Edwards, Stephen M Fleming, Nick C Fox, Robert Howard, Jonathan Huntley, Jeremy D Isaacs, Andrew J Larner, Timothy R Nicholson, Catherine M Pennington, Norman Poole, Gary Price, Jason P Price, Markus Reuber, Craig Ritchie, Martin N Rossor, Jonathan M Schott, Tiago Teodoro, Annalena Venneri, Jon Stone, Alan J Carson
JournalBrain : a journal of neurology (Brain) Vol. 143 Issue 10 Pg. 2895-2903 (10 01 2020) ISSN: 1460-2156 [Electronic] England
PMID32791521 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Copyright© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: [email protected].
Topics
  • Cognition Disorders (diagnosis, epidemiology, psychology)
  • Cognitive Dysfunction (diagnosis, epidemiology, psychology)
  • Dementia (diagnosis, epidemiology, psychology)
  • Diagnosis, Differential
  • Disease Progression
  • Humans

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: